Drugs That Cause Eosinophilic Pneumonitis
NSAIDs (particularly naproxen, ibuprofen, and diclofenac), antibiotics (especially beta-lactams, nitrofurantoin, minocycline, daptomycin, and imipenem/cilastatin), methotrexate, 5-ASA compounds (sulfasalazine), anti-TNF biologics, and antituberculosis agents are the primary drugs that cause eosinophilic pneumonitis. 1, 2, 3, 4
High-Risk Medication Classes
NSAIDs
- Naproxen is the most commonly reported NSAID causing eosinophilic pneumonitis, with 8 published cases plus 3 additional cases in the French pharmacovigilance database 3, 4
- Ibuprofen (3 published cases, 2 in French database) and diclofenac (2 published cases) are also significant culprits 3
- Fenbufen (4 cases), piroxicam (1 case), and other NSAIDs have been documented 3
- The FDA label for naproxen specifically lists "eosinophilic pneumonitis" as an adverse reaction 5
Antibiotics
- Beta-lactam antibiotics are common causes of drug-induced eosinophilic pneumonitis 1, 6
- Nitrofurantoin is a well-established cause 2, 6
- Daptomycin and minocycline are commonly reported antibiotic causes 7
- Imipenem/cilastatin can cause acute eosinophilic pneumonia, with recurrence upon rechallenge 7
Immunosuppressive and Anti-Inflammatory Agents
- Methotrexate causes severe hypersensitivity pneumonitis or pulmonary fibrosis 1
- 5-ASA compounds (sulfasalazine, mesalamine) induce different types of interstitial lung disease, with peripheral eosinophilia in almost half of cases 1
- Anti-TNF monoclonal antibodies can cause granulomatous inflammation and organizing pneumonia patterns 1, 2
Cancer Therapeutics
- EGFR-TKIs (gefitinib, erlotinib, osimertinib, afatinib) cause pneumonitis with pulmonary eosinophilia patterns in 0.55-4.77% of patients 2
- ALK inhibitors (alectinib, brigatinib, ceritinib, crizotinib) cause pneumonitis in 1.14-6.25% of patients 2
- PD-1 inhibitors (nivolumab, pembrolizumab) cause pneumonitis in 2.7-6.6% of patients 2
- Bleomycin is a classic anticancer agent causing eosinophilic pneumonitis 2, 4
Other Medications
- Anticonvulsants, particularly phenytoin 6
- Sulfonamide-containing antibiotics 6
- Gold salts (historically important, now less common) 8
- Chinese herbal medicines 8
- Antituberculosis agents 8
Clinical Presentation and Timing
Onset Patterns by Drug Class
- Anti-inflammatory drugs, analgesics, and antibiotics: Typically develop at 1-2 weeks after starting administration 8
- Anticancer and immunosuppressive agents: Often delayed onset with features of diffuse interstitial pneumonia 8
- Chinese herbal medicines, gold salts: Intermediate timing at 2-6 months 8
Key Clinical Features
- Dyspnea, fever, chest pain, and cough are the most common symptoms 1
- Peripheral eosinophilia is found in almost half of cases with 5-ASA compounds 1
- Bronchoalveolar lavage shows elevated eosinophils (>15% is diagnostic) 3, 7
- Ground-glass opacities and consolidation on chest CT 2, 7
Diagnostic Approach
The diagnosis requires temporal relationship to drug exposure, exclusion of infections and other causes, and demonstration of eosinophilia in blood or bronchoalveolar lavage. 2, 3, 4
- Obtain detailed medication history including exact timing of drug initiation 2
- Perform chest CT showing organizing pneumonia, NSIP, DAD, hypersensitivity pneumonitis, or simple pulmonary eosinophilia patterns 2
- Check peripheral eosinophil count (though may be normal) 8
- Bronchoscopy with BAL showing >15% eosinophils is diagnostic 3, 7
- Drug lymphocyte stimulation test (DLST) has high sensitivity for NSAIDs, antibiotics, and anti-inflammatory drugs but low sensitivity for anticancer agents 8
Management Algorithm
- Immediately discontinue the suspected offending drug 3, 4, 7
- Initiate corticosteroid therapy for severe or refractory cases (typically prednisolone 30 mg daily, then taper) 9, 3, 4
- Monitor for clinical improvement within days to weeks 3, 7
- Never rechallenge with the causative drug, as recurrence is expected 4, 7
Critical Pitfalls
- Do not assume eosinophilia is drug-related without first excluding helminthic infections, especially in travelers or migrants 6
- Infections (particularly opportunistic infections in immunosuppressed patients) must always be excluded before attributing pneumonitis to drugs 1, 2
- Japanese patients have significantly higher incidence of EGFR-TKI pneumonitis (4.77% vs 0.55% in non-Japanese) 2
- Metastatic disease can mimic drug-induced pneumonitis on imaging 2
- Tapering corticosteroids too rapidly can cause recurrence, as demonstrated in the rheumatoid arthritis case where symptoms returned when prednisolone was reduced to 5 mg daily 9
Prognosis
- Anti-inflammatory drugs, analgesics, and antibiotics: Generally good outcome with drug discontinuation and corticosteroids 8
- Anticancer and immunosuppressive agents: Generally poor outcome with higher mortality 8
- All patients in published NSAID-induced eosinophilic pneumonitis cases recovered with appropriate management 3